Human Trials

Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints

Celgene Corporation has announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.

VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma

VBI Vaccines has announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system.

Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study

Roche announced that its lung cancer drug Tecentriq (atezolizumab) has significantly improved overall survival (OS) rate in the phase III IMpower110 study.

Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis

Merck announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).

Esketamine nasal spray reduces depressive symptoms in two phase 3 studies

Janssen Pharmaceutical said that the esketamine nasal spray along with the comprehensive standard of care (SOC) has met the primary efficacy endpoints of two phase 3 trials featuring adult patients with a major depressive disorder.

AstraZeneca’s Imfinzi significantly improves OS in phase III SCLC trial

AstraZeneca announced that its Imfinzi (durvalumab) has significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC) in the phase III Caspian study.

Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study

Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction (HFrEF).

VALBIOTIS announces additional positive results from phase IIA clinical study of VALEDIA

VALBIOTIS has announced additional positive results from its Phase IIA clinical study of VALEDIA on four parameters which were among the secondary endpoints of the study: blood triglyceride levels, Fatty Liver Index, (fat accumulation in the liver), blood LDL cholesterol levels, and arterial hypertension.

Roche’s one-dose Xofluza meets primary endpoint in phase III flu study of children

Roche’s one-dose Xofluza (baloxavir marboxil) has achieved primary endpoint in phase III MINISTONE-2 study of children with flu.